EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

In silico and in vitro evaluation of the potential genotoxic impurities of vildagliptin

Muhammed Hamitoğlu, Gulcin Tugcu, Ayşe Gökçen Kılıç, Gülşah Esen, Ahmet Aydin

Naunyn-Schmiedeberg's Archives of Pharmacology · 2025-07 · 398 (7) · 8629-8638

DOI: 10.1007/s00210-024-03781-6 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, online erschienen am 21.01.2025. Verfasst von Muhammed Hamitoğlu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Toxicology, Faculty of Pharmacy, Yeditepe University, 34755, Ataşehir, Istanbul, Turkey. mohammad.saz@yeditepe.edu.tr. Hauptthemen laut MEDLINE: Vildagliptin, Drug Contamination, Mutagens, Pyrrolidines. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Yeditepe University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Establishing the safety of impurities in drug substances or products is crucial. The assessment of genotoxicity for these impurities and determining the acceptable limits pose considerable challenges, as recognized in recent guidelines. While the genotoxicity profile of vildagliptin—an oral hypoglycemic drug—is well established, there is limited knowledge about the genotoxic potential of its impurities. In this study, vildagliptin cyclic amidine, vildagliptin diketopiperazine, and vildagliptin amide were assessed in silico and in vitro for mutagenic and clastogenic/aneugenic potential using Ames and micronucleus tests. None of the investigated impurities showed mutagenic or clastogenic potential, thus, are considered non-mutagenic and non-clastogenic/aneugenic in vitro. These findings are consistent with negative in silico predictions for mutagenicity and clastogenicity/aneugenicity in vitro, indicating a good correlation between in silico and in vitro data. In conclusion, this study provides valuable information for the safety assessment of vildagliptin, confirming that its impurities are neither clastogenic/aneugenic nor mutagenic.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

VildagliptinDrug ContaminationMutagensPyrrolidinesNitrilesAdamantaneDipeptidyl-Peptidase IV InhibitorsHypoglycemic AgentsMutagenicity TestsComputer SimulationAnimalsHumansMicronucleus Tests

Stichwörter der Autor:innen

Bacterial reverse mutation assayClastogenicityICHIn silicoMicronucleus testMutagenicity

Substanzen

VildagliptinMutagensPyrrolidinesNitrilesAdamantaneDipeptidyl-Peptidase IV InhibitorsHypoglycemic Agents

Autor:innen und Institutionen

  • Department of Toxicology, Faculty of Pharmacy, Yeditepe University, 34755, Ataşehir, Istanbul, Turkey. mohammad.saz@yeditepe.edu.tr.
  • Department of Toxicology, Faculty of Pharmacy, Yeditepe University, 34755, Ataşehir, Istanbul, Turkey.

Förderung

  • Yeditepe University

Zitieren

APA

Hamitoğlu, M., Tugcu, G., Kılıç, A. G., Esen, G., & Aydin, A. (2025). In silico and in vitro evaluation of the potential genotoxic impurities of vildagliptin. Naunyn-Schmiedeberg's Archives of Pharmacology, 398(7), 8629-8638. https://doi.org/10.1007/s00210-024-03781-6

Vancouver

Hamitoğlu M, Tugcu G, Kılıç AG, Esen G, Aydin A. In silico and in vitro evaluation of the potential genotoxic impurities of vildagliptin. Naunyn-Schmiedeberg's Archives of Pharmacology. 2025;398(7):8629-8638. doi:10.1007/s00210-024-03781-6

BibTeX
@article{Hamitolu2025,
  author = {Hamitoğlu, Muhammed and Tugcu, Gulcin and Kılıç, Ayşe Gökçen and Esen, Gülşah and Aydin, Ahmet},
  title = {In silico and in vitro evaluation of the potential genotoxic impurities of vildagliptin},
  journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
  year = {2025},
  volume = {398},
  number = {7},
  pages = {8629--8638},
  doi = {10.1007/s00210-024-03781-6}
}
Kostenlos starten →